Back to results
US 8,410,069 B2Granted
Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer
AssigneeQuark Pharmaceuticals, Inc.
InventorElena Feinstein
Life of this patent
Estimating the term…
Abstract
The invention provides novel double stranded oligoribonucleotides that inhibit the Nrf2 gene. The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also relates to methods and compositions for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
Claims26
A double-stranded RNA compound having the structure:
- 5′ (N)x-Z 3′
- (antisense strand)
- 3′ Z′-(N′)y 5′
- (sense strand)
- wherein each N and N′ is a ribonucleotide which may independently be modified or unmodified in its sugar residue;
- wherein each of (N)x and (N′)y is an oligomer in which each consecutive N or N′ is joined to the next N or N′ by a covalent bond;
- wherein each of x and y is an integer between 19 and 40;
- wherein each of Z and Z′ may be present or absent, but if present is 1-5 consecutive nucleotides covalently attached at the 3′ terminus of the strand in which it is present;
- and wherein the sequences of (N)x and (N′)y are complementary and the sequence of (N)x comprises SEQ ID NO. 622 and the sequence of (N′)y comprises SEQ ID NO:119.
6 more elements
A double-stranded RNA compound having the structure:
- wherein each of A, C, G and U is an unmodified or a 2′O-methyl sugar modified ribonucleotide and each consecutive ribonucleotide is joined to the next ribonucleotide by a covalent bond;
- and
- wherein each vertical line represents base pairing between the ribonucleotides.
Dependencies are inferred from the claim text.